COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats by Peter J Hotez, Lois Privor-Dumm, Melanie Saville, Jerome H Kim, Sarah Gilbert, Salim Abdool-Karim, Didi Thompson, Jean-Louis Excler

“…The challenge of COVID-19 vaccine inequity, as COVID-19 spread globally, created a situation where cutting-edge mRNA technologies were preferentially supplied by multinational pharmaceutical companies to high-income countries while low and middle-income countries (LMICs) were pushed to the back of the queue and relied more heavily on adenoviral vector, inactivated virus and recombinant protein vaccines. …”
Get full text

Availability of different branded generic vildagliptin after off-patenting: An observation from India by Shambo S Samajdar, Shatavisa Mukherjee, Sougata Sarkar, Sumalya Sen, Santanu Kumar Tripathi, Shashank R Joshi

“…Further research and interventions should be undertaken to improve coordination between healthcare providers, pharmaceutical companies, and pharmacy stores, aiming to enhance the availability and accessibility of affordable generics without compromising patient care.…”
Get full text

Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study by Dutescu IA, Hillier SA

“…However, despite increasing rates of antibiotic resistance, pharmaceutical companies are reluctant to develop new antibiotics due to scientific, regulatory, and financial barriers. …”
Get full text

Complexity of design in early phase respiratory clinical trials; evaluating impact of primary endpoints and sponsor size by Nicolas Marco-Ariño, Alexandra Jauhiainen, Joanne Betts, Carla A. Da Silva

“…We hypothesised that small and mid-sized pharmaceutical companies may be innovative in the selection of their trial endpoints, to be time- and cost-effective. …”
Get full text

New Molecular Insights into the Inhibition of Dipeptidyl Peptidase-4 by Natural Cyclic Peptide Oxytocin by Veera C. S. R. Chittepu, Poonam Kalhotra, Tzayhri Osorio-Gallardo, Cristian Jiménez-Martínez, Raúl René Robles-de la Torre, Tzayhri Gallardo-Velazquez, Guillermo Osorio-Revilla

“…Protease inhibition has led to treating many diseases and has been successful in producing many commercial drugs by pharmaceutical companies. Among many proteases, serine protease has been attractive in treating metabolic disorder diabetes mellitus (DM). …”
Get full text

Updates on Management of Helicobacter pylori Infection and Antibiotic Resistant Helicobacter Infection Management by Saskia Aziza Nursyirwan, Marcellus Simadibrata

“…Triple bismuth therapy and quadruple bismuth therapy are used less frequently due to their inherent complexity, the large number of tablets four times a day, side effects, and lack of support from pharmaceutical companies. Inclusively, vonoprazan is also a good choice that is fully effective from day one. …”
Get full text

Progress toward therapeutic potential for AFQ056 in Fragile X syndrome by Sourial M, Cheng C, Doering LC

“…To offset the deficits caused by the lack of FMRP, many pharmaceutical companies have designed medicinal drugs to target the unrestrained stimulation of mGluR5 signaling in FXS. …”
Get full text

Saudi anti-human cancer plants database (SACPD): A collection of plants with anti-human cancer activities by Ateeq Ahmed Al-Zahrani

“…SACPD will provide an excellent starting point for researchers and pharmaceutical companies who are interested in developing new anticancer drugs. …”
Get full text

The definition of placebo in the informed consent forms of clinical trials. by Astrid Hernández, Josep-E Baños, Cristina Llop, Magí Farré

“…RESULTS: Two thousand seven-hundred and forty research protocols were evaluated, of which three hundred and fifty-nine used a placebo. Pharmaceutical companies sponsored most placebo-controlled clinical trials (91.9%), and phase III studies were the commonest (59.9%). …”
Get full text

A Validated HPLC Method for Quantitation of Rosmarinic Acid in a Polyherbal Syrup by Sara Zakerin, Homa Hajimehdipoor, Seyed Alireza Mortazavi*, Rasool Choopani, Shirin Fahimi, Masoumeh Sabetkasaei, Fatemeh Tavakolifar

“…The syrup is a good candidate for pharmaceutical companies after pharmacological and clinical tests.…”
Get full text

Evolving role of pharmaceutical physicians in medical evidence and education by Setia S, Ryan NJ, Nair PS, Ching E, Subramaniam K

“…Sajita Setia,1 Nicola J Ryan,2 Prasad S Nair,3 Elma Ching,3 Kannan Subramaniam4 1Medical Affairs, Pfizer Pte Ltd, Singapore; 2Independent Medical Writing Services, Auckland, New Zealand; 3Department of Pharmacy, National University of Singapore, Singapore; 4Global Medical Affairs, Asia-Pacific Region, Pfizer Australia, West Ryde, NSW, Australia Abstract: The role of pharmaceutical physicians who are the experts working in pharmaceutical companies has progressed over the last few decades, from supervising research and development (R&D) studies and/or providing support to marketing teams to serving an independent critical function. …”
Get full text

Survey on perceptions of Indian investigators on research ethics by Sutinder Bindra, Puja Kochhar

“…Whether research related ethical principles around informed consent, adverse event (AE) reporting, post trial drug commitments and others are being observed, merits evaluation Methods: A specially designed survey questionnaire was served to 29 investigators in India, having prior experience of participating in drug development studies with pharmaceutical companies. The survey included questions on investigator profile, study design, informed consent process, safety reporting, patient and physician compensation, post trial drug commitments among others. …”
Get full text

Transformations of Medical and Vaccine Diplomacies in the COVID-19 Era by I. I. Arsentyeva

“…The article examines the current policy of China, as it has achieved the most notable success in medical services export, primarily to developing countries, and Chinese pharmaceutical companies play a prominent role in the global vaccine market. …”
Get full text

ETHICAL ISSUES IN MEDICAL PUBLISHING by Matjaž Zwitter

“…To an increasing degree, pharmaceutical companies and other commercial sponsors initiate, support, and define priorities of clinical research. …”
Get full text

How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea by SeungJin Bae, Joohee Lee, Eun-Young Bae

“…Purpose: We aimed to describe the types of uncertainties examined in the economic evaluations submitted for reimbursement in Korea and their impact on the incremental cost-effectiveness ratio (ICER).Method: Fifty dossiers were submitted by pharmaceutical companies to the economic subcommittee of the Pharmaceutical Benefit Coverage Advisory Committee (PBCAC) from January 2014 to December 2018. …”
Get full text

Conformal efficiency as a metric for comparative model assessment befitting federated learning by Wouter Heyndrickx, Adam Arany, Jaak Simm, Anastasia Pentina, Noé Sturm, Lina Humbeck, Lewis Mervin, Adam Zalewski, Martijn Oldenhof, Peter Schmidtke, Lukas Friedrich, Regis Loeb, Arina Afanasyeva, Ansgar Schuffenhauer, Yves Moreau, Hugo Ceulemans

“…In a drug discovery setting, pharmaceutical companies own substantial but confidential datasets. …”
Get full text

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy by Entela Xoxi, Karen M Facey, Americo Cicchetti

“…The technological architecture of the registries is funded by pharmaceutical companies, but fully governed by the national medicines agency (AIFA). …”
Get full text

MONTRA2: A web platform for profiling distributed databases in the health domain by João Rafael Almeida, José Luís Oliveira

“…The users’ requirements were designed in the context of the EHDEN European project, in close collaboration with medical researchers, data owners, and pharmaceutical companies, leading to a rich set of functionalities to support databases and cohorts discovery. …”
Get full text

A questionnaire survey of consumers, pharmacists and wholesale retailers of state regulation of parapharmaceutical goods by A. S. Nemchenko, , V. I. Mishchenko

“…Most part of the respondents (50%) noted that the financial crisis has slowed down pharmaceutical companies work, by reducing consumer demand for parapharmaceutical and preference for medicines purchasing. 40% of managers pointed to the difficulties in work with parapharmaceutical goods because of the minimum amount of purchases from the manufacturer.…”
Get full text

The COVID-19 Vaccination Strategy in Brazil—A Case Study by Llanos Bernardeau-Serra, Agathe Nguyen-Huynh, Lara Sponagel, Nathalia Sernizon Guimarães, Raphael Augusto Teixeira de Aguiar, Milena Soriano Marcolino

“…Official documents from the Brazilian Ministry of Health, the website of the World Health Organization and pharmaceutical companies were also reviewed. Searches were limited to English, French, German, Portuguese and Spanish. …”
Get full text